Comparison of calcium-channel blockers for longterm clinical outcomes in patients with vasospastic angina
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Calcium channel blockers (CCBs) are the most widely prescribed medication for patients with vasospastic angina (VA). However, few studies have compared the prognosis of VA patients who are prescribed different CCBs. Methods: We enrolled 2,960 patients who received provocation test prospectively in 11 university hospitals in Korea. We divided 1,586 patients received four major CCBs into two groups: a first generation CCB (diltiazem and nifedipine) group and a second generation CCB (amlodipine and benidipine) group. Primary outcome was time to events of composite of death from any cause, acute coronary syndrome (ACS) and symptomatic arrhythmia during 3-year follow-up. We also compared the effect of each CCB on the control of angina symptoms. Results: There was no difference of the primary outcome among the two groups with a cumulative incidence rate of 5.4%, 2.9%, and a person-month incidence rate of 2.33 and 1.26, respectively (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.25 to 1.17; p = 0.120, as reference with the 1st generation CCBs). The incidence of ACS was significantly lower in 2nd generation CCBs group with a person-month incidence rate of 1.66 vs. 0.35 (HR, 0.22; 95% CI, 0.05 to 0.89; p = 0.034). Use of benidipine showed a significant better control of angina symptom compared with diltiazem for 3 years (odds ratio, 0.17; 95% CI, 0.09 to 0.32; p < 0.0001 at 3rd year). Conclusions: The first and second generation CCB groups did not differ in terms of composite outcome occurrence. However, the ACS incidence rate was significantly lower in the users of the 2nd generation CCBs.
Abstract
Background/Aims: Calcium channel blockers (CCBs) are the most widely prescribed medication for patients with vasospastic angina (VA). However, few studies have compared the prognosis of VA patients who are prescribed different CCBs. Methods: We enrolled 2,960 patients who received provocation test prospectively in 11 university hospitals in Korea. We divided 1,586 patients received four major CCBs into two groups: a first generation CCB (diltiazem and nifedipine) group and a second generation CCB (amlodipine and benidipine) group. Primary outcome was time to events of composite of death from any cause, acute coronary syndrome (ACS) and symptomatic arrhythmia during 3-year follow-up. We also compared the effect of each CCB on the control of angina symptoms. Results: There was no difference of the primary outcome among the two groups with a cumulative incidence rate of 5.4%, 2.9%, and a person-month incidence rate of 2.33 and 1.26, respectively (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.25 to 1.17; p = 0.120, as reference with the 1st generation CCBs). The incidence of ACS was significantly lower in 2nd generation CCBs group with a person-month incidence rate of 1.66 vs. 0.35 (HR, 0.22; 95% CI, 0.05 to 0.89; p = 0.034). Use of benidipine showed a significant better control of angina symptom compared with diltiazem for 3 years (odds ratio, 0.17; 95% CI, 0.09 to 0.32; p < 0.0001 at 3rd year). Conclusions: The first and second generation CCB groups did not differ in terms of composite outcome occurrence. However, the ACS incidence rate was significantly lower in the users of the 2nd generation CCBs.
참고문헌 (26)
- Shimokawa H, "Clinical characteristics and long-term prognosis of patients with variant angina. A comparative study between western and Japanese populations", Int J Cardiol, 18, pp.331~349 (1988)
- 유상용, "변이형 협심증 환자의 장기 예후 및 임상적 특징", Korean Circulation Journal, 38(12), pp.651~658 (2008), 대한심장학회
- Choi BG, "Five-year clinical outcomes in patients with significant coronary artery spasm : a propensity score-matched analysis", Int J Cardiol, 184, pp.533~539 (2015)
- Kim YH, "Five-year major clinical outcomes according to severity of coronary artery spasm as assessed by intracoronary acetylcholine provocation test", Arch Cardiovasc Dis, 111, pp.144~154 (2018)
- Ito A, "Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers", J Cardiovasc Pharmacol, 44, pp.480~485 (2004)
- Ahn JM, "Prognosis of variant angina manifesting as aborted sudden cardiac death", J Am Coll Cardiol, 68, pp.137~145 (2016)
- Rodriguez-Manero M, "Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm", Europace, 20, pp.851~858 (2018)
- Cho SW, "Clinical outcomes of vasospastic angina patients presenting with acute coronary syndrome", J Am Heart Assoc, 5, pp.e004336~ (2016)
- JCS Joint Working Group, "Guidelines for diagnosis and treatment of patients with vasospastic angina(Coronary Spastic Angina)(JCS 2013)", Circ J, 78, pp.2779~2801 (2014)
- Amsterdam EA, "2014 AHA", ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 64[DOI]
- Kimura E, "Treatment of variant angina with drugs : a survey of 11 cardiology institutes in Japan", Circulation, 63, pp.844~848 (1981)
- Higuma T, "Comparison of the effects of long-acting nifedipine CR and diltiazem R in patients with vasospastic angina : Aomori coronary spastic angina study", J Cardiol, 56, pp.354~360 (2010)
- Schroeder JS, "Prevention of cardiovascular events in variant angina by long-term diltiazem therapy", J Am Coll Cardiol, 1, pp.1507~1511 (1983)
- Nishigaki K, "Prognostic effects of calcium channel blockers in patients with vasospastic angina : a meta-analysis", Circ J, 74, pp.1943~1950 (2010)
- Chahine RA, "Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group", J Am Coll Cardiol, 21, pp.1365~1370 (1993)
- Shin DI, "The 24-month prognosis of patients with positive or intermediate results in the intracoronary ergonovine provocation test", JACC Cardiovasc Interv, 8, pp.914~923 (2015)
- Fukumoto Y, "Prognostic effects of benidipine in patients with vasospastic angina : comparison with diltiazem and amlodipine", J Cardiovasc Pharmacol, 51, pp.253~257 (2008)
- Wang CH, "Coronary vasospasm as a possible cause of elevated cardiac troponin I in patients with acute coronary syndrome and insignificant coronary artery disease", Am Heart J, 144, pp.275~281 (2002)
- Ong P, "Coronary artery spasm as a frequent cause of acute coronary syndrome : The CASPAR(Coronary Artery Spasm in Patients With Acute Coronary Syndrome)Study", J Am Coll Cardiol, 52, pp.523~527 (2008)
- Grossman E, "Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure", Am J Cardiol, 80, pp.1453~1458 (1997)
- Miwa Y, "Differential effects of calcium-channel blockers on vascular endothelial function in patients with coronary spastic angina", Circ J, 73, pp.713~717 (2009)
- Io K, "Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test", Arzneimittelforschung, 57, pp.573~581 (2007)
- Minatoguchi S, "Vasospastic angina and Ca channel blockers", Curr Hypertens Rev, 9, pp.219~223 (2013)
- Karasawa A, "Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1, 4-dihydropyridine derivative, in isolated canine coronary arteries", Jpn J Pharmacol, 47, pp.35~44 (1988)
- Suzuki H, "Clinical efficacy of benidipine for vasospastic angina pectoris", Arzneimittelforschung, 57, pp.20~25 (2007)
- 박태식, "Impact of Diltiazem Alone versus Diltiazem with Nitrate on Five-Year Clinical Outcomes in Patients with Significant Coronary Artery Spasm", Yonsei Medical Journal, 58(1), pp.90~98 (2017), 연세대학교의과대학[DOI]